Hematology Transfusion and Cell Therapy

Our screening does not flag Hematology Transfusion and Cell Therapy. That is not a guarantee of quality — it means the venue is not on Beall's archive (frozen since 2017) and does not match our name-pattern heuristic. It is listed in DOAJ, Scopus, Web of Science, PubMed, which is a positive signal.

Per our venue index, Hematology Transfusion and Cell Therapy appears in: DOAJ, Scopus, Web of Science, PubMed. Index membership changes over time — confirm on the index's own site before relying on it.

Papers in Hematology Transfusion and Cell Therapy are cited about 0.1 times each within two years of publication, and Scimago places it in Q3, with an h-index of 31. Those are the open equivalents: the Clarivate Journal Impact Factor is a proprietary metric we neither compute nor license, so we show the two-year citation rate and Scimago quartile instead — they answer the same question of how heavily the journal is cited. A citation rate is a property of a field as much as of a journal.

In the Scimago Journal Rank 2025 edition, Hematology Transfusion and Cell Therapy is Q3 in 1 of its 2 subject categories and Q4 in the other 1. By category: Hematology: Q3, #98 of 151; Immunology and Allergy: Q4, #178 of 236. Its best category quartile is Q3. Quartiles split the journals in a subject category into four equal groups by SJR, so Q1 is the most-cited quarter and Q4 the least; Hematology Transfusion and Cell Therapy is cited about 0.1 times per paper over two years, with an h-index of 31.

The Web of Science quartile comes from Clarivate's Journal Citation Reports (JCR), a proprietary product we neither license nor compute — so we cannot state a JCR quartile for Hematology Transfusion and Cell Therapy. The open equivalent is its best Scimago quartile, Q3 in Hematology, derived from Scopus citation data. Because JCR ranks against Web of Science and Scimago against Scopus, the two can differ, so check Clarivate's site directly if you need the JCR quartile specifically.

Our index records its access status as "gold". Where this is derived from publisher-level signals rather than works-level data it is a heuristic, so confirm on the journal's own site — particularly if an article processing charge matters to you.

Free to publish — DOAJ lists no article processing charge (APC). So there is no fee for authors to publish in Hematology Transfusion and Cell Therapy. Fee policies change — confirm on the journal's own site before relying on it.

Submission to publication for Hematology Transfusion and Cell Therapy takes about ~30 wk — DOAJ self-reported. Treat it as indicative rather than a guarantee: editorial times vary by article type, reviewer availability and season, and a self-reported figure is the journal's own. We do not hold a peer-review acceptance rate for Hematology Transfusion and Cell Therapy.